Form D · Pharmaceuticals
Processa Pharmaceuticals, Inc.
Hanover, MD · CIK 0001533743
Offering snapshot reported Feb 19, 2021 · SEC filing
- Reported sold
- $10.2M Offering amount: $10.2M
- Investors reported
- 18 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Feb 16, 2021 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Feb 19, 2021 | Initial | $10,238,773 | No comparison | 18 | SEC filing |
| May 16, 2018 | Initial | $2,525,694 | No comparison | 33 | SEC filing |
| Dec 27, 2017 | Amendment | $2,580,000 | $0vs Dec 5, 2017 | 23 | SEC filing |
| Dec 5, 2017 | Initial | $2,580,000 | No comparison | 23 | SEC filing |
| Mar 24, 2015 | Initial | $25,500 | No comparison | 3 | SEC filing |
| Feb 20, 2015 | Initial | $90,000 | No comparison | 3 | SEC filing |
| Nov 13, 2014 | Initial | $75,000 | No comparison | 1 | SEC filing |
| Oct 27, 2014 | Initial | $173,825 | No comparison | 15 | SEC filing |
| Jan 13, 2014 | Initial | $175,000 | No comparison | 6 | SEC filing |
| Jan 10, 2014 | Initial | $250,000 | No comparison | 1 | SEC filing |
| Sep 30, 2013 | Amendment | $2,182,944 | No comparison | 51 | SEC filing |
| Jul 12, 2013 | Initial | Yet to sell | No comparison | 0 | SEC filing |
| Jun 24, 2013 | Initial | Yet to sell | No comparison | 0 | SEC filing |
| May 28, 2013 | Initial | $1,000,000 | No comparison | 7 | SEC filing |
| Aug 10, 2012 | Initial | $1,520,000 | No comparison | 44 | SEC filing |
| Oct 28, 2011 | Initial | Yet to sell | No comparison | 0 | SEC filing |
Offering details
- Securities
- Equity, Option to acquire
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $307K
- Finders' fees
- $0
- Form D file number
- 021-389915
The Issuer will also issue warrants to the placement agent to purchase up to 79,268 shares of common stock for an exercise price of $9.30 for cash for a period of two years.
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| Tribal Capital Markets, LLC | 38901 |
Source: Form D, filed Feb 19, 2021. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Sian Bigora | Executive |
| Gus Blass Iii | Director |
| Allen Dodge | Executive |
| David Dworsky | Director, Executive |
| Michael Floyd | Executive |
| Stephan Garland | Director |
| Stephen Garland | Director |
| Richard Giles | Director |
| Reginald Greenslade | Director |
| Larry Griffin | Director, Executive |
| Wendy Guy | Executive |
| Khalid Islam | Director |
| Heather Kearns | Executive |
| Alex Kramer | Executive |
| Donald Larson | Director |
| Patrick Lin | Executive |
| Geraldine Pannu | Director |
| Helen Pentikis | Executive |
| James Stanker | Executive |
| Virgil Thompson | Director |
| Hugh Wolff | Director |
| Justin York | Director |
| Justin W. Yorke | Director |
| David Young | Director, Executive |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
7380 Coca Cola Drive Suite 106
Hanover, MD, 21076
Hanover, MD, 21076